Mirtazapin Al (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Al, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on patient safety and therapeutic consistency. Our supply chain ensures timely delivery and compliance with import regulations.

Mirtazapine is used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Depressive episodes in adults: helps alleviate sadness, loss of interest, and functional impairment. - Depression with insomnia: provides antidepressant effect while improving sleep quality in patients experiencing depressive insomnia.

Common Side Effects: - Sedation: feeling unusually drowsy or sleepy. - Increased appetite: heightened desire for food, often leading to weight gain. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headedness, especially when standing quickly. - Weight gain: gradual increase in body weight over time.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, increasing infection risk. - Suicidal thoughts: emergence or worsening of suicidal ideation, particularly early in treatment. - Severe hypersensitivity: rash, swelling, or anaphylactic reactions. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Hepatic dysfunction: abnormal liver enzyme elevations indicating liver injury.

Before initiating therapy, evaluate patient history and monitor for specific concerns.

- Assess suicidal risk: monitor closely during the first weeks of treatment. - Evaluate hepatic function: use caution in patients with liver impairment. - Monitor weight changes: advise patients about potential weight gain. - Caution with CNS depressants: avoid excessive sedation when combined with alcohol or benzodiazepines. - Review concomitant serotonergic drugs: consider risk of serotonin syndrome. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and direct light.

Mirtazapine may interact with several drug classes; careful review is required.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, triptans): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Antihypertensives: potential additive hypotensive effect. - Carbamazepine: may reduce mirtazapine concentrations, decreasing efficacy. - Warfarin: possible alteration of INR, requiring closer coagulation monitoring.